Bli medlem
Bli medlem

Du är här


Neurovive Pharmaceutical: NeuroVive strengthens its organization with the recruitment of Cecilia Hofvander as IR and Communications Director

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine
company, announces that it has recruited Cecilia Hofvander as
Investor Relations and Communications Director effective from 1 June
2016 in order to strengthen the company's communication resources.

Cecilia Hofvander joins NeuroVive from Active Biotech AB where she has
worked for 15 years, the last eight as Assistant Director Investor
Relations & Business Development. She holds a B.Sc in Chemistry and
Molecular Biology from Lund University and has completed the
Communication Executive Program at the Stockholm School of Economics.

"One of my priorities as NeuroVive's new CEO is to strengthen our
communication team. Cecilia's communications expertise combined with
her experience of the biotech industry will make a valuable
contribution," commented NeuroVive's CEO Erik Kinnman.

Apart from IR and Communication, Cecilia Hofvander's broad experience
includes business development, financial transactions and
international clinical trials with drug candidates.

"NeuroVive has a very promising project portfolio and is in an
exciting phase with the results of clinical trials due to be
presented over the coming year. I look forward to contributing to the
company's development by communicating NeuroVive's and its partners'
activities and drug development progress. In my communication work,
my priorities are openness and clarity as a means to building
long-term relationships with the company's stakeholders," commented
Cecilia Hofvander.

Christine Tadgell from InVentive Health will coordinate NeuroVive's
external communication in the period until Cecilia Hofvander takes up
her position with NeuroVive. The company's collaboration with IR firm
Laika Consulting will also continue.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial
medicine and a company committed to the discovery and development of
highly targeted candidates that preserve mitochondrial integrity and
function in areas of significant therapeutic need. NeuroVive's
business approach is driven by value-adding partnerships with
mitochondrial research institutions and commercial partners across
the globe. NeuroVive's portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with
candidates in clinical and preclinical development and two drug
discovery platforms. The NeuroSTAT® product has orphan drug status in
Europe and in the US for treatment of moderate to severe traumatic
brain injury and is currently being evaluated in a study, CHIC.
Ciclosporin is being evaluated in an on-going study, CiPRICS, in
acute kidney injury during major surgery. NeuroVive's shares are
listed on Nasdaq, Stockholm, Sweden.

For investor relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)275 62 21 or

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48,

NeuroVive Pharmaceutical AB (publ) is required to publish the
information in this news release under The Swedish Securities Market
Act. The information was submitted for publication on 08.30 CET on 11
April 2016.

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine
company. The company is listed on NASDAQ OMX Stockholm, Small Cap,
under the ticker symbol NVP. The share is also traded on the OTC
market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the
OTC Pink Market. Investors can find Real-Time quotes and market
information for the company at


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.